Clinical Trials

A Phase I/II Study of AT7519M with and without Bortezomib in Patients with Previously Treated Multiple Myeloma

Protocol
10-151
Full Title
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination with Bortezomib in Patients with Previously Treated Multiple Myeloma
Purpose

Multiple myeloma, a cancer of the bone marrow, often recurs after initial therapy. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called AT7519M in patients with multiple myeloma that persists or has returned despite at least two previous regimens of chemotherapy.

AT7519M works by inhibiting enzymes that multiple myeloma cells need to grow and multiply. It will be evaluated alone and in combination with bortezomib, a drug that is already routinely used to treat multiple myeloma. AT7519M is given intravenously (by vein).

Investigator
Heather J. Landau, MD
Heather J. Landau - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has progressed or returned despite at least two prior regimens of chemotherapy.
  • At least 4 weeks must have passed since completion of prior chemotherapy and 2 weeks since any prior radiation therapy and entry into the study.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Heather Landau at 212-639-8808.

Disease(s)
Hematology: Multiple Myeloma
Locations
Related Diseases